Bioasis Technologies (BIOAF) 0.9530 $BIOAF
BTV-Business Television - biOasis Technologies Enters into License Agreement with a Major Pharmaceutical Company
Newsfile Corp - Fri Apr 04, 1:14PM CDT
full story)
biOasis Presents Results From It's BT2111 Program at International Cancer Research Conference
Marketwire - Thu Apr 03, 8:04AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, will present results from it's BT2111 program at the 105th Annual Meeting of the American Academy of Cancer Research (AACR) being held April 5th to 9th, 2014, in San Diego, California.
BTV Highlights Life Sciences with Amgen, Aurora Spine and NeoStem
Marketwire - Thu Apr 03, 5:01AM CDT
BTV goes on location to bring investors stories on emerging companies for their portfolio.
biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend
Marketwire - Mon Mar 17, 8:05AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
biOasis Technologies to list its stock in OTCQX Marketplace in the US
M2 - Tue Feb 25, 6:11AM CST
biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) said on Monday that it has upgraded the listing of its stock to the highest tier of the off-market, OTCQX, under the symbol BIOAF.
biOasis to Begin Trading on OTCQX(R) Marketplace in the U.S.
Marketwire - Mon Feb 24, 8:05AM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis to Begin Trading on OTCQX® Marketplace in the U.S.
Marketwire Canada - Mon Feb 24, 8:02AM CST
biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCQX:BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis Technologies Begins Trading on OTCQX®
PR Newswire - Mon Feb 24, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that biOasis Technologies Inc. (TSX.V: BTI; OTCQX: BIOAF), a Vancouver-based biopharmaceutical company focused on developing a proprietary brain delivery platform ("Transcend"
to enable existing and create new drugs that address unmet medical needs in the treatment of brain diseases, has been approved to trade on OTCQX®, the best marketplace with qualified companies.
Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis
M2 - Thu Feb 13, 10:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqg5p5/global_lithium) has announced the addition of the "Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis" report to their offering. Lithium-ion battery demand is expected to see a robust growth in the forecast period. This is due to its increasing demand across various application sectors such as automotive, wind, electronics, industrial and military. The market is currently driven by its usage in automotive sector in HEVs, trains and trams. Lithium-ion batteries can be differentiated primarily based on their functionality. The application of lithium-ion battery alongside other batteries is expected to increase, and lithium-ion batteries are expected to emerge as a replacement for lead acid batteries in the coming years. This report has been segmented by material type, by application and by geography. It also includes the drivers, restraints and opportunities (DROs), Porter's five forces analysis and value chain of the lithium-ion battery market. The study highlights current market trends and provides the forecast from 2013 to 2019. Scope of the Report Material Type - Cathode - Anode - Electrolytic Solution - Others (Binders, Separators etc) Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Lithium-Ion Battery Market Analysis, By Material Type Chapter 5 Lithium-Ion Battery Market Analysis, By Application Chapter 6 Lithium-Ion Battery Market Analysis And Forecast, By Geography Chapter 7 Company Profiles - A123 Systems Llc - Automotive Energy Supply Corporation (Aesc) - China Bak Battery Co Ltd - Ga Yuasa Corporation - Hitachi Chemical Co Ltd - Johnson Controls, Inc - Lg Chem Power, Inc - Panasonic Corporation - Samsung Sdi Co Ltd - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/zq...al_lithium
Urban Airship Reveals Industry's Current State of Mobile Maturity
Marketwire - Thu Feb 13, 10:16AM CST
Urban Airship, the global leader in Mobile Relationship Management, today published its inaugural Mobile Maturity Benchmarks Report showcasing the industry's progress in moving towards more personalized, sustained audience engagement strategies versus more traditional, one-size-fits-all messaging and marketing tactics. Top-level findings indicate that 85 percent of companies have gone beyond mobile web sites, mobile search and traditional reach-and-frequency marketing to drive sustained engagement strategies through mobile apps. However, the majority of those companies (56 percent) deliver the same messages and app experience to all users -- not yet unlocking mobile's unique benefits of intimacy, immediacy and context. Other findings uncovered that nearly one-third of companies that collect user-specific data don't yet use it to tailor content and messaging.
Option Grant-biOasis Technologies Inc.
Marketwire - Wed Dec 04, 4:46PM CST
biOasis Technologies Inc. (TSX VENTURE: BTI) (the "Company" announces that, pursuant to the terms of its Stock Option Plan, the company has granted a total of 1,700,000 options to its officers, employees, consultants and members of the board of directors. 1,550,000 of the options are exercisable at a price of $0.97 per share until December 3, 2018 and 150,000 of the options are exercisable at a price of $0.97 per share until December 5, 2014. The options shall vest according to the Company's stock option plan.
Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone
Marketwire - Tue Nov 12, 8:05AM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCBB: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research conducted under its BT2111 (Herceptin(R)) program shows that BT2111-a conjugate of the metastatic cancer drug, Herceptin-not only crosses the blood-brain barrier, but also penetrates the blood-tumor barrier up to 10 times better than Herceptin alone.
BTV-Business Television - biOasis Technologies Enters into License Agreement with a Major Pharmaceutical Company
Newsfile Corp - Fri Apr 04, 1:14PM CDT
full story)
biOasis Presents Results From It's BT2111 Program at International Cancer Research Conference
Marketwire - Thu Apr 03, 8:04AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, will present results from it's BT2111 program at the 105th Annual Meeting of the American Academy of Cancer Research (AACR) being held April 5th to 9th, 2014, in San Diego, California.
BTV Highlights Life Sciences with Amgen, Aurora Spine and NeoStem
Marketwire - Thu Apr 03, 5:01AM CDT
BTV goes on location to bring investors stories on emerging companies for their portfolio.
biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend
Marketwire - Mon Mar 17, 8:05AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
biOasis Technologies to list its stock in OTCQX Marketplace in the US
M2 - Tue Feb 25, 6:11AM CST
biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) said on Monday that it has upgraded the listing of its stock to the highest tier of the off-market, OTCQX, under the symbol BIOAF.
biOasis to Begin Trading on OTCQX(R) Marketplace in the U.S.
Marketwire - Mon Feb 24, 8:05AM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis to Begin Trading on OTCQX® Marketplace in the U.S.
Marketwire Canada - Mon Feb 24, 8:02AM CST
biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCQX:BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis Technologies Begins Trading on OTCQX®
PR Newswire - Mon Feb 24, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that biOasis Technologies Inc. (TSX.V: BTI; OTCQX: BIOAF), a Vancouver-based biopharmaceutical company focused on developing a proprietary brain delivery platform ("Transcend"
to enable existing and create new drugs that address unmet medical needs in the treatment of brain diseases, has been approved to trade on OTCQX®, the best marketplace with qualified companies. Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis
M2 - Thu Feb 13, 10:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqg5p5/global_lithium) has announced the addition of the "Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis" report to their offering. Lithium-ion battery demand is expected to see a robust growth in the forecast period. This is due to its increasing demand across various application sectors such as automotive, wind, electronics, industrial and military. The market is currently driven by its usage in automotive sector in HEVs, trains and trams. Lithium-ion batteries can be differentiated primarily based on their functionality. The application of lithium-ion battery alongside other batteries is expected to increase, and lithium-ion batteries are expected to emerge as a replacement for lead acid batteries in the coming years. This report has been segmented by material type, by application and by geography. It also includes the drivers, restraints and opportunities (DROs), Porter's five forces analysis and value chain of the lithium-ion battery market. The study highlights current market trends and provides the forecast from 2013 to 2019. Scope of the Report Material Type - Cathode - Anode - Electrolytic Solution - Others (Binders, Separators etc) Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Lithium-Ion Battery Market Analysis, By Material Type Chapter 5 Lithium-Ion Battery Market Analysis, By Application Chapter 6 Lithium-Ion Battery Market Analysis And Forecast, By Geography Chapter 7 Company Profiles - A123 Systems Llc - Automotive Energy Supply Corporation (Aesc) - China Bak Battery Co Ltd - Ga Yuasa Corporation - Hitachi Chemical Co Ltd - Johnson Controls, Inc - Lg Chem Power, Inc - Panasonic Corporation - Samsung Sdi Co Ltd - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/zq...al_lithium
Urban Airship Reveals Industry's Current State of Mobile Maturity
Marketwire - Thu Feb 13, 10:16AM CST
Urban Airship, the global leader in Mobile Relationship Management, today published its inaugural Mobile Maturity Benchmarks Report showcasing the industry's progress in moving towards more personalized, sustained audience engagement strategies versus more traditional, one-size-fits-all messaging and marketing tactics. Top-level findings indicate that 85 percent of companies have gone beyond mobile web sites, mobile search and traditional reach-and-frequency marketing to drive sustained engagement strategies through mobile apps. However, the majority of those companies (56 percent) deliver the same messages and app experience to all users -- not yet unlocking mobile's unique benefits of intimacy, immediacy and context. Other findings uncovered that nearly one-third of companies that collect user-specific data don't yet use it to tailor content and messaging.
Option Grant-biOasis Technologies Inc.
Marketwire - Wed Dec 04, 4:46PM CST
biOasis Technologies Inc. (TSX VENTURE: BTI) (the "Company"
announces that, pursuant to the terms of its Stock Option Plan, the company has granted a total of 1,700,000 options to its officers, employees, consultants and members of the board of directors. 1,550,000 of the options are exercisable at a price of $0.97 per share until December 3, 2018 and 150,000 of the options are exercisable at a price of $0.97 per share until December 5, 2014. The options shall vest according to the Company's stock option plan. Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone
Marketwire - Tue Nov 12, 8:05AM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCBB: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research conducted under its BT2111 (Herceptin(R)) program shows that BT2111-a conjugate of the metastatic cancer drug, Herceptin-not only crosses the blood-brain barrier, but also penetrates the blood-tumor barrier up to 10 times better than Herceptin alone.
